Active on improving trials

ACRES, ActivMed partner for quality and sustainability of clinical research sites
| 3 min read
Register for free to listen to this article
Listen with Speechify
0:00
3:00
CAMBRIDGE, Mass.—The Alliance for Clinical Research Excellence and Safety (ACRES), a non-profit organization building a global system for clinical research, and ActivMed Practices & Research Inc., a woman-owned, for-profit, multispecialty, free-standing research organization, have created a strategic alliance to enhance clinical research site standards, accreditation and training, as well as community-based site development programs. The partnership aims to enhance the quality and sustainability of clinical research sites.
ActivMed will participate in ACRES’ ongoing Site Accreditation and Standards Initiative to improve performance of global research sites through shared standards, accreditation, training and support. ActivMed participation will start with membership in a Phase 3 standards domain team involving personnel and professionalism criteria.
Continue reading below...
A black mosquito is shown on pink human skin against a blurred green backdrop.
InfographicsDiscovering deeper insights into malaria research
Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Read More
ActivMed, which has access to nearly one million patients and a full range of clinical studies, will also collaborate with ACRES in the testing of developed standards and processes for ACRES site accreditation work. Other areas of shared interest include professional development programs for research staff that can be offered within local communities as well as online and the development of education and training programs.
“The creation of a systems-based approach to promote high-performing clinical research sites and to properly reward the work they do is long-overdue,” said Terry Stubbs, ActivMed founder, president and CEO. “The value proposition is clear: we believe this is a terrific opportunity for sites committed to quality, like ActivMed, to get involved and to have real impact.”
According to Greg Koski, ACRES co-founder and CEO, “We are delighted that a growing number of sites and site organizations worldwide are aligning with the ACRES vision. ActivMed is committed to quality in every dimension of its work in clinical research, and it now brings this commitment to this global collaboration.”
Continue reading below...
A white, pink, and blue 3D molecular structure of a simple sugar is shown against a light purple background.
WebinarsAdding a little sugar: what glycomics can bring to medicine
Discover how glycoscience is transforming how scientists understand diseases and opening new doors for drug discovery.
Read More
Stubbs had learned about ACRES at a presentation done by Koski during a MAGI conference. She “was excited about the industry changes that may be coming and how it would affect us at the site,” adding, “At sites, we know things need to change, but we have very little power to do so. Unless all players get on the same page about what works and what does not work, the industry will continue to waste money trying to do things the ‘old and broken way.’ Creating one system that can be used all over the world makes perfect sense.”
After attending another conference in Boston for ACRES, Stubbs decided that she wanted to be part of this new alliance and was willing to donate time and effort to help move things forward. She and Koski agreed that changes were needed and more people needed to be willing to donate time to move this imitative forward at a faster pace.
Continue reading below...
An illustration of various colored microbes, including bacteria and viruses
WebinarsCombatting multidrug-resistant bacterial infections
Organic molecules with novel biological properties offer new ways to eliminate multidrug-resistant bacteria.
Read More
In terms of objectives, Dr. Mary Tobin, special advisor to the president and CEO of ACRES, explains, “With all ACRES strategic alliances, now approaching 100, there is an overall commitment to collaborate in building the global system to increase quality, accountability, safety and excellence in clinical research. Then, depending on the individual strategic alliance partner, engagement involves projects associated with one or more of ACRES' different initiatives.”
According to Tobin, ActivMed site work “falls naturally into ACRES sites initiative, which includes many aspects of site excellence, such as accreditation and standards and the global network of sites.” Because systems elements are always connected, elements of other initiatives “may cross over, such as quality assurance systems, global ethical and regulatory innovation, the development of a product safety culture or certainly patient engagement efforts, and underpinning all initiatives is the global technology platform,” she says.
“While other organizations may work with a few other stakeholders, none have brought together a comprehensive multistakeholder consortium focused on both a systems approach and a drive towards implementation. As a global non-profit operating in the public interest, ACRES is ideally positioned to facilitate cooperation among all of the stakeholders. ACRES began by envisioning a new future, and the alliance has risen to the challenge of creating it … this is an exciting time, and it will have dramatic impact for decades to come,” Tobin adds.
Continue reading below...
A syringe with a needle drawing the vaccine out of a vial with ampules in the background
InfographicsTurbocharging mRNA vaccine development
Cell-free gene synthesis technology offers a quick, reliable route to creating vital mRNA vaccines and therapeutics.
Read More
Stubbs wants to help create courses that can be offered at no cost or low cost to sites and proper training programs within local areas. She hopes to be changing systems so that staff can start work already knowing the ins and outs of research, instead of having to learn almost everything on the job.
Stubbs said, “We all have lots of years of experience working in the field of clinical research. Each ACRES ally comes with its own personal gifts of accumulated knowledge, depending on what area of research it works in. We can bring this knowledge to the table and share with each other. We can find what works and does not work and push the good ideas ahead to share with the industry. ACRES has created the largest and most representative alliance ever assembled in the name of strategic transformation of this endeavor. ACRES’ reach and focus is global, and its approach is inclusive and collaborative, one in which all stakeholders can take part and benefit.”
Continue reading below...
A 3D illustration of blue antibodies floating toward a green colored virus
InfographicsImmunotherapy for infectious diseases
Many of the same therapies used to activate the immune system against cancer may also combat infectious diseases.
Read More
“Dramatic changes such as remote risk-based monitoring and auditing, real-time performance management, regulatory innovation and simplification will completely transform the way we do things today; everyone will benefit, and the world will become a healthier, more productive place for all,” Tobin concludes.

About the Author

Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Close-up of a researcher using a stylus to draw or interact with digital molecular structures on a blue scientific interface.
When molecules outgrow the limits of sketches and strings, researchers need a new way to describe and communicate them.
Portrait of Scott Weitze, Vice President of Research and Technical Standards at My Green Lab, beside text that reads “Tell us what you know: Bringing sustainability into scientific research,” with the My Green Lab logo.
Laboratories account for a surprising share of global emissions and plastic waste, making sustainability a priority for modern research.
3D illustration of RNA molecules on a gradient blue background.
With diverse emerging modalities and innovative delivery strategies, RNA therapeutics are tackling complex diseases and unmet medical needs.
Drug Discovery News September 2025 Issue
Latest IssueVolume 21 • Issue 3 • September 2025

September 2025

September 2025 Issue

Explore this issue